Bellicum Pharmaceuticals Receives $20,000,000 Series B Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f3bbd6d6-f410-4771-b328-86ceebfe82f2&Preview=1
Date
3/12/2012
Company Name
Bellicum Pharmaceuticals
Mailing Address
6400 Fannin St. Houston, TX 77030
Company Description
Bellicum Pharmaceuticals, Inc. is developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum’s novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response.
Website
http://www.bellicum.com
Transaction Type
Venture Equity
Transaction Amount
$20,000,000
Transaction Round
Series B
Proceeds Purposes
The funding will be used to advance its lead CaspaCIDe and DeCIDe programs through Phase 2 clinical development.
M&A Terms
Venture Investor
Remeditex Ventures
Venture Investor
Undisclosed